all-trans-retinol/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases bronchopulmonary dysplasia of any grade at 36 weeks
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“Vitamin A therapy reduced BPD among survivors (RR=0.86 [95% CI: 0.75–0.98]) with a greater effect among infants at low risk than high risk of BPD or death (p=0.01 for interaction).”
Quoted verbatim from Should Vitamin A Injections to Prevent Bronchopulmonary Dysplasia or Death Be Reserved for High-Risk Infants? Reanalysis of the National Institute of Child Health and Human Development Neonatal Research Network Randomized Trial.. - Study
- RCT
- Duration
- 4 weeks
- Dose
- 5000 IU intramuscularly three times weekly for 4 weeks versus sham procedure
- Population
- Infants of 401-1000 g birth weight on respiratory support at 24 hours, randomised to intramuscular vitamin A or sham; BPD among survivors to 36 weeks postmenstrual age (post hoc reanalysis of the NICHD Neonatal Research Network trial)
Effect 0.86 risk ratio, 95% CI 0.75 to 0.98
Should Vitamin A Injections to Prevent Bronchopulmonary Dysplasia or Death Be Reserved for High-Risk Infants? Reanalysis of the National Institute of Child Health and Human Development Neonatal Research Network Randomized Trial.2021PMID:34004189Permalink
Keep reading
- Everything the graph holds on all-trans-retinol
- Every compound studied against Bronchopulmonary dysplasia of any grade at 36 weeks
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M5JSSWYSM1AHK4VX7VCZ3E7G